UNSPSC 51402306: Enciprazine dihydrochloride

This classification denotes an anxiolytic with the molecular formula C23H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YTO3CZ93HM, chemically known as 1-piperazineethanol, 4-(2-methoxyphenyl)-.alpha.-((3,4,5-trimethoxyphenoxy)methyl)-, dihydrochloride, (+/-)-, but more generally known as enciprazine dihydrochloride, which bears US NIH Compound Identifier 50221.

European Medicines Agency schedules enciprazine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06520MIG. Most nations, for tariff purposes, schedule enciprazine dihydrochloride under HS 29335995. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CC(C(C(C3)OC)OC)OC)O.CL.CL.

UNSPSC 51402306 Enciprazine dihydrochloride is a Commodity code that captures pharmaceutical products state and local governments procure for health and human services delivery, though recent solicitations show the code in practice spans naloxone, generic multi-source pharmaceuticals, and OTC products rather than the specific compound named. Issuing bodies range from county health departments and state health and human services agencies to multistate cooperative purchasing alliances coordinating procurement across multiple jurisdictions. Seminole County, Florida solicited naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, conducted a formal RFP for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon.

Recent activity is concentrated in the South and Upper Midwest, with solicitations posted from Florida, Texas, and Minnesota in the first half of 2026. The Seminole County IFB (Solicitation IFB60459723LAS) required electronic submission through the county's e-Procurement Portal with a response deadline of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI (HHS0017013) closed April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription contracting; and the MMCAP RFP (S1070000015802) closed March 26, 2026, seeking manufacturers to supply generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awarded contracts effective July 1, 2026. Evaluations in the MMCAP solicitation weighted price competitiveness at 75 percent, with vendors required to maintain $5,000,000 commercial general liability and $2,000,000 professional liability coverage. Federal funding influences some procurements—the Seminole County contract noted potential FEMA funding with Clean Air Act and Federal Water Pollution Control Act compliance requirements—while MMCAP applies a 3 percent administrative fee on all contract purchases.